{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-276826","form_type":"8-K","ticker":"WHWK","cik":"0001422142","company_name":"Whitehawk Therapeutics, Inc.","filed_at":"2021-09-20T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.056081+00:00","generated_at":"2026-06-29T02:35:42.087563+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aadi Bioscience appoints Brendan Delaney as COO effective Sept 20, 2021","bullets":["Delaney previously Chief Commercial Officer at Constellation Pharmaceuticals (acquired by MorphoSys for $1.4B) and Immunomedics.","Annual base salary of $480,000, target bonus of 45%, and option to purchase 260,000 shares vesting over 4 years.","Severance includes 12 months base salary plus COBRA reimbursement; full acceleration of equity upon change-in-control termination.","Company highlights upcoming PDUFA date of Nov 26, 2021 for ABI-009 in PEComa and plans to initiate registrational trial for TSC1/TSC2 alterations.","Delaney will establish Aadi's East Coast presence; has prior roles at Celgene/BMS and Novartis."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-276826","json":"https://secwatch.observer/filing/0001193125-21-276826.json","markdown":"https://secwatch.observer/filing/0001193125-21-276826.md","text":"https://secwatch.observer/filing/0001193125-21-276826.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422142/000119312521276826/0001193125-21-276826-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422142/000119312521276826/d234049d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T02:35:42.087563+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"69ee4d6920","claim":"Brendan Delaney was appointed as Chief Operating Officer at Whitehawk Therapeutics, Inc..","evidence_excerpt":"On September 19, 2021, Aadi Bioscience, Inc. (the “ Company ”) appointed Brendan Delaney as the Company’s Chief Operating Officer, effective September 20, 2021","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000119312521276826/0001193125-21-276826-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}